Association of genetically enhanced lipoprotein lipase–mediated lipolysis and low-density lipoprotein cholesterol–lowering alleles with risk of coronary disease and type 2 diabetes
<strong>Importance</strong> Pharmacological enhancers of lipoprotein lipase (LPL) are in preclinical or early clinical development for cardiovascular prevention. Studying whether these agents will reduce cardiovascular events or diabetes risk when added to existing lipid-lowering drugs...
Asıl Yazarlar: | Lotta, LA, Stewart, ID, Sharp, SJ, Day, FR, Burgess, S, Luan, J, Bowker, N, Cai, L, Li, C, Wittemans, LBL, Kerrison, ND, Khaw, K-T, McCarthy, MI, O'Rahilly, S, Scott, RA, Savage, DB, Perry, JRB, Langenberg, C, Wareham, NJ |
---|---|
Materyal Türü: | Journal article |
Baskı/Yayın Bilgisi: |
American Medical Association
2018
|
Benzer Materyaller
-
Association of genetically enhanced lipoprotein lipase-mediated lipolysis and low-density lipoprotein cholesterol-lowering alleles with risk of coronary disease and type 2 diabetes
Yazar:: Lotta, L, ve diğerleri
Baskı/Yayın Bilgisi: (2018) -
Association between low-density lipoprotein cholesterol-lowering genetic variants and risk of type 2 diabetes: a meta-analysis
Yazar:: Lotta, L, ve diğerleri
Baskı/Yayın Bilgisi: (2016) -
Peningkatan rasio Low Density Lipoprotein Cholesterol dengan High Density Lipoprotein Cholesterol sebagai faktor resiko stroke iskemik
Yazar:: , ARITYAWAN, Fred Septo, ve diğerleri
Baskı/Yayın Bilgisi: (2007) -
Genome-wide association study of adipocyte lipolysis in the GENetics of adipocyte lipolysis (GENiAL) cohort
Yazar:: Kulyté, A, ve diğerleri
Baskı/Yayın Bilgisi: (2020) -
In vitro and in vivo lipolysis of plasma triglycerides increases the resistance to oxidative modification of low-density lipoproteins.
Yazar:: Skoglund-Andersson, C, ve diğerleri
Baskı/Yayın Bilgisi: (2003)